Ashley N Brown,
PRG DIR & ASO PROF
Department:
MD-INST FOR THERAPEUTIC INNOV
Business Phone:
(407) 313-7063
Business Email:
ashleybrown@ufl.edu
Teaching Profile
Courses Taught
2019-2021
PHA7979 Advanced Research
2016-2018,2020
PHA5755 Micro, Immun, Virol
2018-2020,2022
PHA7980 Research for Doctoral Dissertation
2019-2021
PHA6133 Translational Clinical Pharmacology
2018
GMS7979 Advanced Research
2017
PHA6935 Selected Topics in Pharmacy
2022-2024
PHA5782C Patient Care 2: Introduction to Infectious Disease and Oncology
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-9993-5241
Publications
2024
Environmental surface monitoring as a noninvasive method for SARS-CoV-2 surveillance in community settings: Lessons from a university campus study.
The Science of the total environment.
912
[DOI] 10.1016/j.scitotenv.2023.169456.
[PMID] 38123097.
2023
A five-day treatment course of zanamivir for the flu with a single, self-administered, painless microneedle array patch: Revolutionizing delivery of poorly membrane-permeable therapeutics.
International journal of pharmaceutics.
641
[DOI] 10.1016/j.ijpharm.2023.123081.
[PMID] 37230371.
2023
Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression
Viruses.
15(5)
[DOI] 10.3390/v15051175.
[PMID] 37243261.
2023
Evidence of a Sjögren’s disease-like phenotype following COVID-19 in mice and humans.
JCI insight.
8(24)
[DOI] 10.1172/jci.insight.166540.
[PMID] 37676726.
2023
Favipiravir Inhibits Zika Virus (ZIKV) Replication in HeLa Cells by Altering Viral Infectivity
Microorganisms.
11(5)
[DOI] 10.3390/microorganisms11051097.
[PMID] 37317071.
2023
Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen
Microorganisms.
11(5)
[DOI] 10.3390/microorganisms11051342.
[PMID] 37317316.
2023
Structure-Based Design of Potent Iminosugar Inhibitors of Endoplasmic Reticulum α-Glucosidase I with Anti-SARS-CoV-2 Activity
Journal of Medicinal Chemistry.
66(4):2744-2760
[DOI] 10.1021/acs.jmedchem.2c01750.
[PMID] 36762932.
2022
UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines.
Frontiers in bioscience (Landmark edition).
27(1)
[DOI] 10.31083/j.fbl2701003.
[PMID] 35090308.
2022
Why Molnupiravir Fails in Hospitalized Patients.
mBio.
13(6)
[DOI] 10.1128/mbio.02916-22.
[PMID] 36374076.
2021
Antiviral Activity of the PropylamylatinTM Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions
Viruses.
13(3)
[DOI] 10.3390/v13030415.
[PMID] 33807769.
2021
Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus
Viruses.
13(5)
[DOI] 10.3390/v13050771.
[PMID] 33925551.
2021
Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines
Microorganisms.
9(2)
[DOI] 10.3390/microorganisms9020307.
[PMID] 33540830.
2020
Modeling the viral dynamics of SARS-CoV-2 infection.
Mathematical biosciences.
328
[DOI] 10.1016/j.mbs.2020.108438.
[PMID] 32771304.
2018
A sensitive electrochemical immunosensor for label-free detection of Zika-virus protein.
Scientific reports.
8(1)
[DOI] 10.1038/s41598-018-28035-3.
[PMID] 29946074.
2018
Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM).
Viruses.
10(6)
[DOI] 10.3390/v10060317.
[PMID] 29890736.
2018
Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy.
62(9)
[DOI] 10.1128/AAC.00967-18.
[PMID] 29967017.
2018
Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
111:443-449
[DOI] 10.1016/j.ejps.2017.10.027.
[PMID] 29079337.
2018
The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines
Antiviral Chemistry and Chemotherapy.
26
[DOI] 10.1177/2040206618807580.
[PMID] 30354193.
2018
Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer.
Frontiers in pharmacology.
9
[DOI] 10.3389/fphar.2018.00403.
[PMID] 29765318.
2018
Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens.
Antimicrobial agents and chemotherapy.
62(1)
[DOI] 10.1128/AAC.01983-17.
[PMID] 29109164.
2017
Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
Pharmacological research.
124:20-33
[DOI] 10.1016/j.phrs.2017.07.015.
[PMID] 28735000.
2017
Reply to Scagnolari et al.
The Journal of infectious diseases.
215(3):493-494
[DOI] 10.1093/infdis/jiw580.
[PMID] 28003357.
2017
Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.
Antiviral research.
146:149-152
[DOI] 10.1016/j.antiviral.2017.09.001.
[PMID] 28882564.
2017
Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-15007-2.
[PMID] 29089577.
2016
Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a.
The Journal of infectious diseases.
214(8):1192-7
[DOI] 10.1093/infdis/jiw358.
[PMID] 27496974.
2015
Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.
Antimicrobial agents and chemotherapy.
59(7):3771-7
[DOI] 10.1128/AAC.00469-15.
[PMID] 25870053.
2015
Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
mBio.
6(6):e01741-15
[DOI] 10.1128/mBio.01741-15.
[PMID] 26530386.
2012
Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.
Antimicrobial agents and chemotherapy.
56(3):1170-81
[DOI] 10.1128/AAC.05383-11.
[PMID] 22155837.
2011
Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.
Antimicrobial agents and chemotherapy.
55(4):1747-53
[DOI] 10.1128/AAC.01629-10.
[PMID] 21263045.
2011
Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.
Antimicrobial agents and chemotherapy.
55(4):1740-6
[DOI] 10.1128/AAC.01628-10.
[PMID] 21263046.
2010
In vitro system for modeling influenza A virus resistance under drug pressure.
Antimicrobial agents and chemotherapy.
54(8):3442-50
[DOI] 10.1128/AAC.01385-09.
[PMID] 20498316.
2010
Persistence of West Nile virus in the central nervous system and periphery of mice.
PloS one.
5(5)
[DOI] 10.1371/journal.pone.0010649.
[PMID] 20498839.
2007
Tissue tropism and neuroinvasion of West Nile virus do not differ for two mouse strains with different survival rates.
Virology.
368(2):422-30
[PMID] 17675128.
Grants
Jan 2023
– May 2023
Testing of SARS-CoV2 inhibitors in cell-based infection assays
Role: Principal Investigator
Funding: PARDES BIOSCIENCES
Oct 2021
– Dec 2021
Rapid Inactivation of SARS-CoV-2 Variants by Puradigm Technology
Role: Principal Investigator
Funding: PURADIGM LLC
Jul 2021
– Sep 2022
Are We Truly Protected- Assessment of Immunity Protection Against Mutating COVID-19 Strains & Assay Development
Role: Principal Investigator
Funding: ABSS SOLUTIONS
via US AIR FORCE
Feb 2021
– Jun 2021
Evaluation of air purification methods for SARS-CoV-2
Role: Principal Investigator
Funding: HELEN OF TROY
Dec 2020
– Jun 2021
COVID-19: Monoclonal Antibody Production
Role: Co-Investigator
Funding: LIFESOUTH COM BLOOD CNTR
Nov 2020
– Jan 2022
Evaluation of escape mutants to ADG20 against SARS-CoV-2 virus using a hollow fiber infection model system
Role: Principal Investigator
Funding: ADAGIO THERAPEUTICS
Jul 2020
– Aug 2020
Rapid Inactivation of SARS-CoV-2 by Puradigm Technology
Role: Principal Investigator
Funding: PURADIGM LLC
Jul 2020
– Jul 2021
COVID-19: Sx and other mixes of acids and esters to inactivate SARS-CoV-2 and other viruses
Role: Principal Investigator
Funding: ECOPLANET
Jun 2020
– Jul 2020
COVID19: Inactivation of SARS-CoV-2 by Puradigm Technology
Role: Principal Investigator
Funding: PURADIGM LLC
Apr 2020
– Jul 2020
COVID-19: Antiviral Evaluations for Four Compounds against a Human SARS-CoV-2 Isolate
Role: Principal Investigator
Funding: GLOBAL BIOLIFE
Apr 2019
– Mar 2022
SBIR: Microneedle Delivery of Zanamivir for Treatment of Influenza Infections
Role: Principal Investigator
Funding: THERAPEUTIC SYSTEMS RES LABORATORIES
via NATL INST OF HLTH NIAID
Jan 2018
– Jun 2019
CZ-02 pharmacodynamic studies, A New Class of Antibiotics Selectively Inhibiting Bacterial Protein Synthesis
Role: Co-Investigator
Funding: CURZA
via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Apr 2017
– Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Mar 2017
– Jun 2018
Identification of antiviral therapies for the treatment of Zika virus using existing drugs
Role: Principal Investigator
Funding: FL DEPT OF HLTH
Dec 2015
– May 2021
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Dec 2015
– Nov 2017
Prevalence and mechanism of baseline Nitroimidazole resistance in MDR and XDR TB
Role: Principal Investigator
Funding: BRIGHAM AND WOMENS HOSPITAL
via NATL INST OF HLTH
Mar 2014
– Feb 2022
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Contact Details
Phones:
- Business:
- (407) 313-7063
Emails:
- Business:
- ashleybrown@ufl.edu
Addresses:
- Business Mailing:
-
6550 SANGER RD
ORLANDO FL 32827 - Business Street:
-
6550 SANGER RD
ORLANDO FL 32827